On November 7, 2023, Amneal Intermediate Inc. (formerly Amneal Pharmaceuticals, Inc.), a Delaware corporation (“Old Amneal”), completed a holding company reorganization (the “Reorganization”) in accordance with Section 251(g) of the General Corporation Law of Delaware and the Agreement and Plan of Merger (the “Merger Agreement”), dated as of November 7, 2023, by and among Old Amneal, Amneal Pharmaceuticals, Inc. (formerly Amneal NewCo Inc.), a Delaware corporation (“New Amneal”), and Amneal Merger Sub 1 Inc., a Delaware corporation and a wholly-owned subsidiary of New Amneal (“Merger Sub 1”), pursuant to which Merger Sub 1 merged with and into Old Amneal (the “Merger”), with Old Amneal surviving as a wholly-owned subsidiary of New Amneal. New Amneal changed its name to “Amneal Pharmaceuticals, Inc.” and Old Amneal changed its name to “Amneal Intermediate Inc.” In connection with the Reorganization, all of the outstanding capital stock of Old Amneal (including any stock options or other rights to acquire the same) was converted automatically, on a share-for-share basis, into equivalent corresponding capital stock of New Amneal (and rights to acquire the same), having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding capital stock being converted. The Merger constitutes a succession for purposes of Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Form 15 relates solely to the reporting obligations of Old Amneal and does not affect the reporting obligations of New Amneal, which is the successor registrant to Old Amneal under the Exchange Act.